The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

Oxford Cannabinoid Technologies reports no adverse events in OCT461201 trial

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) chief executive Clarissa Sowemimo-Coker speaks to Thomas Warner from Proactive London after the pharmaceutical group announced it has successfully administered the final dose of its lead drug candidate, OCT461201, as part of its phase I clinical trial.

Sowemimo-Coker says that no adverse events were reported during the trial, which began in late July. While awaiting the final report, the company remains optimistic about the results. She briefly touches upon the potential move into phase two studies for the compound, saying that external advisor Dr William Paul Farquhar-Smith and Chief Medical Officer Dr. Tim Corn are actively planning these next steps.

Additionally, the company's AGM is slated for Thursday, presenting another opportunity for shareholder engagement. Oxford Cannabinoid Technologies is a pharmaceutical group developing prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the U$ multi-billion pain market. The group is developing OCT461201 as a potential treatment for chemotherapy-induced peripheral neuralgia (CIPN).

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.